Synthes-Stratec shows strong first quarter:
This article was originally published in Clinica
First-quarter business for the Swiss-based orthopaedic trauma company, Synthes-Stratec, showed double digit growth in North America and the rest of the world in local currencies. Only Europe lagged behind, with an increase of 5.8% to SwFr47.5 million ($29 million). Rest of the world sales grew dramatically, by 36.4% in local currencies, to SwFr16.4 million. The largest portion of the company's sales, to the North American market, grew by 18.2% in local terms or by 34.5% in adjusted value to SwFr231.3 million, based largely on the appreciation of the US dollar to the Swiss franc.
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.